All > Graft Vs Host Disease

Neihulizumab for Graft-versus-Host Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Graft-versus-Host DiseaseNeihulizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is to test a new drug, Neihulizumab, to see if it is safe and tolerated by patients with aGVHD.

Eligible Conditions
  • Graft-versus-Host Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Gallium maltolate (recommended phase 2 dose)
1
MSCTC-0010 Dose Escalation
1
Galacto-oligosaccharide

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: 6 months

6 months
Event-free survival.
Non-relapse mortality.
Day 28
Number of DLTs.
Treatment response: Complete response
Treatment response: Partial response
Use of High Dose Steroids
Up to 28 days
Maximum-tolerated dose.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Gallium maltolate (recommended phase 2 dose)
1
MSCTC-0010 Dose Escalation
1
Galacto-oligosaccharide

Trial Design

4 Treatment Groups

Neihulizumab Dose Escalation, 3 mg/kg
1 of 4
Neihulizumab Dose Escalation, 9 mg/kg
1 of 4
Neihulizumab Dose Expansion
1 of 4
Neihulizumab Dose Escalation, 6 mg/kg
1 of 4

Experimental Treatment

16 Total Participants · 4 Treatment Groups

Primary Treatment: Neihulizumab · No Placebo Group · Phase 1

Neihulizumab Dose Escalation, 3 mg/kg
Biological
Experimental Group · 1 Intervention: Neihulizumab, 3 mg/kg · Intervention Types: Biological
Neihulizumab Dose Escalation, 9 mg/kg
Drug
Experimental Group · 1 Intervention: Neihulizumab, 9 mg/kg · Intervention Types: Drug
Neihulizumab Dose Expansion
Drug
Experimental Group · 1 Intervention: Neihulizumab · Intervention Types: Drug
Neihulizumab Dose Escalation, 6 mg/kg
Drug
Experimental Group · 1 Intervention: Neihulizumab, 6 mg/kg · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Sameem M. Abedin, MDLead Sponsor
Sameem Abedin, MDPrincipal InvestigatorMedical College of Wisconsin
3 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a stage 1-3 skin plus stage 1 upper GI.
You have stage 1-3 skin plus stage 1 lower GI.
You have a minimum of stage 1 skin plus stage 1 lower GI plus stage 1 upper GI.
You have stage 1-3 skin and stage 1-4 liver.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top